The gene panel with methylation-related genes and clinical factors for predicting overall survival of endometrial cancer

Risk factors for prognosis of EC

  • Lijuan Jiao The Second Affiliated Hospital Zhejiang University School of Medicine
  • Junyan Li The Second Affiliated Hospital Zhejiang University School of Medicine
  • Jiong Ma The Second Affiliated Hospital Zhejiang University School of Medicine
  • Pu Cheng The Second Affiliated Hospital Zhejiang University School of Medicine
  • Yue Pang The Second Affiliated Hospital Zhejiang University School of Medicine
DOI: https://doi.org/10.5937/jomb0-58710

Sažetak


Background: This study aimed to identify novel methylation-based prognostic biomarkers for endometrial cancer (EC) to facilitate early diagnosis and treatment. To explore methylation-related prognostic markers in endometrial tissue by analyzing TCGA data and to establish a methylation-based risk model for EC patients.

Materials and Methods: We systematically analyzed methylation-related gene expression and prognostic significance in 409 EC patients using TCGA DNA methylation data. DNA methylation biomarkers were identified through consensus clustering and weighted gene co-expression network analysis (WGCNA). The clusterProfiler algorithm was employed to determine key signaling pathways across different subgroups. A gene panel targeting critical DNA methylation sites was subsequently constructed.

Results: A methylation-related prognostic risk model was developed, incorporating five CpG sites: cg01416891, cg00082235, cg01493517, cg03811891, and cg05317207. The model demonstrated strong predictive performance, with high-risk patients exhibiting significantly poorer prognoses compared to low-risk patients. A gene panel was also established to predict prognosis across different EC risk groups.

Conclusion: The methylation-related gene panel model serves as a reliable prognostic biomarker for EC, offering potential for enhanced early diagnosis and personalized treatment strategies.

Reference

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca-Cancer J Clin 2018; 68(1): 7-30.
2. Piulats JM, Guerra E, Gil-Martin M, Roman-Canal B, Gatius S, Sanz-Pamplona R, et al. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 2017; 145(1): 200-7.
3. Jeltsch A, Broche J, Bashtrykov P. Molecular Processes Connecting DNA Methylation Patterns with DNA Methyltransferases and Histone Modifications in Mammalian Genomes. Genes-Basel 2019; 10(5):
4. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res-Fund Mol M 2008; 659(1-2): 40-8.
5. Jin Z, Liu Y. DNA methylation in human diseases. Genes Dis 2018; 5(1): 1-8.
6. Guo W, Zhu L, Yu M, Zhu R, Chen Q, Wang Q. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. Clin Epigenetics 2018; 10(1): 142.
7. Wentzensen N, Bakkum-Gamez JN, Killian JK, Sampson J, Guido R, Glass A, et al. Discovery and validation of methylation markers for endometrial cancer. Int J Cancer 2014; 135(8): 1860-8.
8. Stampoliou A, Arapantoni-Dadioti P, Pavlakis K. Epigenetic mechanisms in endometrial cancer. J Buon 2016; 21(2): 301-6.
9. Haruma T, Nagasaka T, Nakamura K, Haraga J, Nyuya A, Nishida T, et al. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. Plos One 2018; 13(4): e0195655.
10. Tang Q, Cheng J, Cao X, Surowy H, Burwinkel B. Blood-based DNA methylation as biomarker for breast cancer: a systematic review. Clin Epigenetics 2016; 8: 115.
11. Tang Y, Jiang S, Gu Y, Li W, Mo Z, Huang Y, et al. Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. Oncotarget 2017; 8(35): 58199-209.
12. Gu Y, Zou YM, Lei D, Huang Y, Li W, Mo Z, et al. Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma. Sci Rep-Uk 2017; 7(1): 14200.
13. Micevic G, Theodosakis N, Bosenberg M. Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. Clin Epigenetics 2017; 9(34.
14. Dankova Z, Brany D, Dvorska D, Nachajova M, Fiolka R, Grendar M, et al. Methylation status of KLF4 and HS3ST2 genes as predictors of endometrial cancer and hyperplastic endometrial lesions. Int J Mol Med 2018; 42(6): 3318-28.
15. Jia N, Wang J, Li Q, Tao X, Chang K, Hua K, et al. DNA methylation promotes paired box 2 expression via myeloid zinc finger 1 in endometrial cancer. Oncotarget 2016; 7(51): 84785-97.
16. Sheng Y, Wang H, Liu D, Zhang C, Deng Y, Yang F, et al. Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecol Oncol 2016; 140(1): 145-51.
17. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28(6): 882-3.
18. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca-Cancer J Clin 2024; 74(1): 12-49.
19. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497(7447): 67-73.
20. Wever B, van den Helder R, van Splunter AP, van Gent M, Kasius JC, Trum JW, et al. DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self-samples and cervical scrapes. Int J Cancer 2023; 153(2): 341-51.
21. Khatami F, Shahriari S, Aminimoghaddam S, Klashami ZN, Farahani MS, Teimoori-Toolabi L, et al. PTEN promoter methylation and expression in endometrial cancer tissues. Epigenomics-Uk 2023; 15(8): 507-16.
22. van den Helder R, Wever B, van Trommel NE, van Splunter AP, Mom CH, Kasius JC, et al. Non-invasive detection of endometrial cancer by DNA methylation analysis in urine. Clin Epigenetics 2020; 12(1): 165.
23. Bogani G, Dowdy SC, Cliby WA, Ghezzi F, Rossetti D, Frigerio L, et al. Management of endometrial cancer: issues and controversies. Eur J Gynaecol Oncol 2016; 37(1): 6-12.
Objavljeno
2025/06/12
Broj časopisa
Vol. 44 Br. 7 (2025): Journal of Medical Biochemistry
Rubrika
Original paper

Sva prava zadržana (c) 2025 Lijuan Jiao, Junyan Li, Jiong Ma, Pu Cheng, Yue Pang

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.